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ABSTRACT 
 
Purpose of review 
 
Previous perceptions of cirrhosis as a hypocoagulable state have resulted in empirical blood 
product transfusions prior to invasive procedures. We evaluate procedure-related bleeding 
risks in patients with cirrhosis, assess the utility of conventional and newer global coagulation 
tests, and explore evidence surrounding prophylactic transfusion strategies. 
 
Recent findings 
 
Recent literature supports the concept of a rebalanced, albeit fragile, haemostasis equilibrium 
in cirrhosis, with a potential hypercoagulable tendency in stable patients. Standard 
coagulation tests provide a poor reflection of bleeding risks and yet are relied upon for 
transfusion thresholds. Consequently, a sizeable proportion of patients receive unnecessary 
blood products. The role of viscoelastic tests to guide transfusions requires further evaluation. 
 
Summary 
 
In stable cirrhotic patients procedure-related bleeding rates appear low. Prophylactic 
transfusion strategies based on arbitrary thresholds lack evidence of clinical benefit. There is 
a pressing need for point-of-care coagulation tests that represent the complex coagulopathy of 
cirrhosis, and well-powered randomised controlled trials to develop evidence-based pre-
procedure transfusion guidelines. 
 
Introduction 
 
Cirrhosis has been traditionally perceived as a hypocoagulable state, prompting concern 
amongst clinicians over increased risks of bleeding when performing invasive procedures in 
this patient group [1]. As a consequence, it has remained common practice to empirically 
transfuse patients with impaired coagulation parameters with platelets, plasma or pro-
haemostatic agents to reduce bleeding risk. Recent literature has, however, challenged this 
notion by acknowledging the presence of a re-balanced haemostasis equilibrium in stable 
patients with cirrhosis [1-3]. This suggests that conventional concerns over augmented 
bleeding risks in cirrhosis are likely misconceived.  
  
In this review we describe the altered haemostatic profile in patients with cirrhosis, the 
paradoxical pro-thrombotic tendency, and limitations of interpreting standard coagulation 
tests. We review recent literature assessing bleeding risks of invasive procedures in such 
patients, and evaluate whether empirical transfusion strategies and the use of global 
haemostasis assays may play any beneficial role in reducing procedure-related bleeding 
complications.   
 
A rebalanced haemostasis equilibrium in cirrhosis 
 
The liver plays a key role in haemostasis, as the primary site of synthesis for the majority of 
factors involved in coagulation and fibrinolysis. In addition, it produces thrombopoietin, 
which regulates the production of platelets from megakaryocytes. In cirrhosis, impaired 
protein synthesis leads to a marked reduction of both procoagulant factors (factors II, V, VII, 
IX, X, XI, XII) and anti-coagulant factors (anti-thrombin III, protein C and protein S) [2, 3]. 
An exception is von Willebrand factor (VWF), derived from endothelial cells and 
megakaryocytes, which has increased expression due to endothelial dysfunction and reduced 
levels of ADAMTS13, a VWF cleaving protease. VWF promotes platelet adhesion to 
endothelial surfaces, platelet aggregation under high shear stress, and acts as a carrier for the 
procoagulant factor VIII, preventing its degradation. Increased VWF expression thereby leads 
to elevated factor VIII levels [2].   
 
Thrombocytopenia occurs due to splenic sequestration from splenomegaly in portal 
hypertension, increased platelet destruction mediated by platelet-associated 
immunoglobulins, a reduced production of thrombopoietin, as well as toxic effects of ethanol 
on platelet production and function [3]. Unless the platelet count is severely low (<50x109/L) 
thrombocytopenia does not confer increased bleeding risk, as it is offset by higher levels of 
VWF, mediating greater platelet adhesion [2, 4]. In vitro studies have demonstrated normal 
thrombin generation in cirrhosis in the presence of endothelial-derived thrombomodulin, and 
adequate platelet counts (>50x109/L) [5, 6].  
 
Hyper-fibrinolysis has been described in cirrhosis, resulting from elevated levels of tissue 
plasminogen activator and a deficiency of thrombin-activatable fibrinolysis inhibitor; both 
changes are proportional to the severity of liver disease [2, 3]. Not all studies agree though, 
and it is debated whether there may be compensation from a reduction in profibrinolytic 
factors [2].  
 
Table 1 demonstrates the main alterations of haemostasis in cirrhosis. Overall, in stable 
cirrhosis, the normal generation of thrombin as well as the concomitant acquired deficiency 
of both procoagulant and anticoagulant factors restores a balance in haemostasis [2, 3]. This 
rebalanced equilibrium is fragile, and can easily be tipped towards haemorrhage or 
thrombosis in the presence of infection, renal dysfunction or variceal haemorrhage [7]. 
Endogenous heparin-like effects have been demonstrated in cirrhotic patients with bacterial 
infections [8], explaining the role of sepsis as a contributing factor for bleeding. 
 
Additionally, there is evidence to suggest that stable patients with cirrhosis may in fact 
exhibit a pro-thrombotic tendency [9], while bleeding risks appear more related to the degree 
of portal hypertension and collateral vessel formation rather than defective haemostasis [7]. 
The hypercoagulability in cirrhosis is likely to result from an increased Factor VIII to protein 
C ratio, as well as thrombomodulin resistance [10, 11]. 
 
Standard coagulation tests as a measure of bleeding risk in cirrhosis 
 
Misperceptions of the bleeding risk in cirrhosis largely derive from clinicians’ interpretation 
of standard coagulation tests, including prothrombin time (PT), international normalised ratio 
(INR), and activated partial thromboplastin time (APTT). However, as these conventional 
coagulation tests only provide a measure of procoagulant factors and are insensitive to the 
plasma levels of anticoagulant factors, they do not provide an accurate evaluation of the 
altered in-vivo haemostatic balance [2, 12].  
 
Although INR is a marker of protein synthetic dysfunction and forms part of the Model for 
End Stage Liver Disease (MELD) prognostic score, it is a poor indicator for bleeding risk in 
cirrhosis. Thromboplastin calibration uses plasma obtained from patients taking vitamin K 
antagonists, and has not been validated or standardised in liver disease [13]. PT and APTT 
only detect the first 5% of whole thrombin formation, and are performed without adding 
thrombomodulin, therefore they do not reflect levels of activated protein C, a principal 
anticoagulant which relies on thrombomodulin for activation [13]. The lack of reliability of 
PT or INR to assess coagulation status in cirrhosis has been recognised in the Baveno VI 
guidelines [14]. Furthermore, a recent meta-analysis comprising 11 guidelines and 64 studies, 
found only three prospective trials evaluating the use of standard plasma coagulation tests to 
assess coagulopathy and guide peri-operative bleeding management. The meta-analysis was 
not confined to patients with cirrhosis, but concluded there was no robust evidence that 
standard coagulation tests could provide reliable data for assessing coagulopathy, predicting 
bleeding risks or guiding peri-operative haemostatic therapy [15].  
 
Global haemostasis assays to predict bleeding risk in cirrhosis 
 
There has been considerable recent interest in the role of global haemostasis assays, in 
particular whole blood viscoelastic tests (VETs), as potential tools to provide more 
physiologically relevant insights into the coagulopathy of liver disease. Two commercially 
available VETs currently in clinical use include thromboelastography (TEG®, Haemonetics 
Corporation, Braintree, MA, United States) and rotational thromboelastometry (ROTEM® 
Delta, TEM international GmbH, Munich, Germany) [12].  
 
VETs are increasingly being used as point-of-care tests to guide the rapid assessment and 
management of coagulopathies in trauma, surgery and liver transplantation. VETs provide a 
dynamic assessment of haemostasis, evaluating the kinetics of the entire coagulation process 
from initial clot formation to final clot strength, and provide a more comprehensive reflection 
of the interaction between plasma, blood cells and platelets [12].  
 
Literature evaluating the use of VETs does, however, show discrepancies between results. 
Cirrhotic patients have demonstrated normal global haemostasis as assessed by TEG, 
corresponding with the concept of a rebalanced haemostasis equilibrium [16, 17]. In a cohort 
of 273 stable cirrhotic patients, the median and mean TEG parameters were within normal 
limits, although the maximum amplitude (MA) decreased proportionally to the degree of 
thrombocytopenia [16]. An exception to this was patients with cholestatic liver diseases, who 
demonstrated hypercoagulability and higher clot firmness [18]. On the contrary, other recent 
studies have identified a hypocoagulable TEG profile in cirrhosis, indicating slower and less 
stable clot formation compared to healthy controls [12, 19]. In an Italian prospective study of 
261 cirrhotic patients undergoing liver transplantation, TEG values were outside the normal 
reference ranges in 79.3% of patients, with a trend to hypocoagulability [19]. Similarly, in a 
single-centre prospective study of 40 patients with cirrhosis, ROTEM demonstrated 
hypocoagulability despite preserved or increased endogenous thrombin potential [20]. 
 
Attempting to define specific VETs reference ranges for cirrhotic patients, rather than using 
current reference ranges derived from healthy individuals, may provide a more reliable 
estimation of coagulation status and bleeding risks [19], however is likely to prove difficult 
due to expected variability between patients depending on the aetiology and stage of liver 
disease [17].  
 
Other limitations with the use of VETs need to be taken into consideration; platelet 
dysfunction is not detected, factor XIII is not adequately displayed, and the assays are 
insensitive to detect effects of VWF involved in the initiation of clot formation [21]. There 
are also concerns over standardisation of assays and reproducibility of results given inter-
operator variability. A UK quality assurance investigation showed a wide variation of TEG 
results between centres [22]. Consequently, while TEG is being used to guide pro-
haemostatic product repletion during liver transplantation, there remains insufficient evidence 
to support the routine use of VETs as a predictor of bleeding risk in cirrhosis, and further 
evaluation is required. 
 
Paradoxical thrombotic potential and role for anticoagulation in cirrhosis 
 
Contrary to traditional concerns for a predominant haemorrhagic potential, there is growing 
recognition that cirrhotic patients are at increased risk of venous thromboembolism (VTE) [9, 
10, 23]. A recent systematic review and meta-analysis identified an increased risk of deep 
vein thrombosis (7 studies, OR=2.038, 95%CI=1.817-2.285) and pulmonary embolism (5 
studies, OR=1.655, 95%CI=1.042-2.630) in cirrhotic patients compared to controls [23]. A 
higher 30-day mortality rate following VTE in cirrhotic patients was also observed [24, 25].  
 
The one-year incidence of portal vein thrombosis (PVT) in patients with Child Pugh A or B 
cirrhosis was demonstrated at 4.6% [26], increasing to 16.6% in a cohort of patients with 
Child Pugh B or C cirrhosis [27]. The overall prevalence of PVT in cirrhosis is between 10-
25%, often leading to portal hypertensive complications [9]. Anticoagulation is indicated in 
selected cases to prevent extension of the thrombus and in some cases enables splanchnic 
vein recanalisation [9]. A treatment algorithm using anticoagulation with or without TIPS can 
improve outcomes in such patients [28] . 
 
Interestingly, additional benefits of anticoagulation in patients with cirrhosis without PVT 
have been demonstrated. In a single-centre non-blinded randomised controlled trial (RCT) of 
70 patients with Child Pugh B or C cirrhosis, a 48-week course of enoxaparin 4000IU daily 
resulted in a lower incidence of portal vein thrombosis, with no adverse bleeding events. 
Secondary outcomes included fewer decompensation events and a higher survival rate 
compared to the control group. It was hypothesised that a potential protective effect of 
enoxaparin on decompensation events may be mediated through improved intestinal 
microcirculation, thereby reducing enterocyte damage and bacterial translocation [27]. A 
double-blinded multicentre RCT (CIRROXABAN) evaluating the effect of rivaroxaban on 
the development of portal hypertensive complications and 24-month transplant-free survival 
in patients with cirrhosis is currently underway (NCT02643212). 
 
Anticoagulation may also have antifibrotic effects. Micro-vascular ischaemia has been 
implicated as a key factor in the progression of hepatic fibrosis and cirrhosis [29, 30]. 
Wanless proposed that microthrombi occlusion of branches of the portal and hepatic veins 
leads to sinusoidal injury, tissue ischaemia and subsequent areas of parenchymal extinction: 
contiguous hepatocyte apoptosis with replacement by fibrous tissue [30]. Prevention of 
microthrombi through prophylactic anticoagulation may counteract this. Animal models have 
demonstrated an improvement in hepatic fibrosis from low molecular weight heparin or 
warfarin therapy [31, 32]. Interim per-protocol analysis from a UK multicentre open-label 
RCT (WAFT-C) of warfarin therapy in HCV patients post liver transplantation, has shown a 
significant reduction in fibrosis progression one-year post transplantation in the warfarin 
group [33]. Evaluating whether prophylactic anticoagulation could potentially reduce the 
progression of liver fibrosis, through inhibiting the actions of coagulation factors directly on 
hepatic stellate cells, represents an exciting area of future research.  
 
Bleeding rates of invasive procedures in patients with cirrhosis 
 
In view of the lack of standardised tests that reliably predict bleeding risk in cirrhosis, 
invasive procedures in these patients are often met with a degree of unease. However, since 
liver transplantation can feasibly be performed without requiring blood product replacement, 
it suggests that the altered haemostatic profile of cirrhosis does not translate to diffuse 
bleeding risk. Recent studies support this, showing little evidence to suggest a higher 
prevalence of postprocedural bleeding following invasive procedures (Table 2) [34-39].  
 
A multicentre prospective study assessed the frequency of clinically significant bleeding in 
380 cirrhotic patients with or without abnormal coagulation parameters, defined as an INR 
≥1.5 and/or platelet count ≤50x109/L, undergoing both low and high risk invasive procedures 
[34]. No patients received pre-procedural blood product transfusions. In the low-risk 
procedure group, mostly entailing abdominal paracentesis, no patients had clinically 
significant post-procedure bleeding. In the high-risk group, including central venous 
cannulation or percutaneous liver biopsy, three patients in the abnormal coagulation group 
had clinically significant bleeding, but this did not reach statistical significance (p=0.061). 
All three patients with clinically significant bleeding had Child Pugh C cirrhosis, elevated 
INR and low platelet count, and additional contributing factors of sepsis or acute kidney 
impairment (AKI) [34]. Similar patients with an elevated INR and low platelet count 
undergoing high risk procedures, but without additional sepsis or AKI, did not experience 
clinically significant bleeding. This study implies that invasive procedures can be safely 
carried out in stable cirrhotic patients without empirical transfusion of pro-haemostatic 
products; with no pronounced increased bleeding risks in cases of thrombocytopenia and/or 
prolonged INR.  
 
Additionally, in an Italian case series of 363 cirrhotic patients undergoing a total of 852 
invasive procedures, post procedural bleeding was infrequent, occurring in one in every 36 
patients, was more common in patients who underwent repeat procedures, and was unrelated 
to the platelet count, INR, Child Pugh grade, MELD score or risk category of invasive 
procedures. In fact, none of the ten patients with the most deranged coagulation parameters 
experienced post-procedural bleeding, including several cases of uncorrected pre-procedure 
platelet counts of less than 20x109/L or INR values above 2 [37]. 
 
Other studies have evaluated bleeding rates in cirrhotic patients according to specific 
procedure types. In a retrospective USA study of 240 patients undergoing cardiac 
catheterisation, no procedure-related bleeding events or major vascular complications 
occurred. INR values ranged from 0.93 to 2.35. 17 patients received fresh frozen plasma 
(FFP) pre-procedure, in most cases without a significant reduction in INR. No correlation 
was found between post-procedure changes in haemoglobin and INR values [35]. 
 
A small retrospective Korean study of 30 patients with predominantly Child Pugh grade A or 
B cirrhosis undergoing colonoscopy with polypectomy, found a low rate of immediate post-
polypectomy bleeding. The mean prothrombin time of patients was 1.3, and the mean platelet 
count was 137x109/L. Only 2/66 polyp removals resulted in mild oozing, which was 
controlled by the application of haemoclips, with no delayed post-polypectomy bleeding [36].  
 
A large retrospective single centre study in USA analysing complications from 3357 
percutaneous liver biopsies performed with Klatskin needles across a 36-year period, 
identified a low total bleeding rate of 0.6% (21/3357 biopsies) [38]. Patients with bleeding 
complications had higher total bilirubin and alkaline phosphatase levels, and lower albumin 
levels. The median pre-biopsy platelet count, PT and APTT did not differ between patients 
that did or did not experience bleeding complications, however multivariate backward 
stepwise logistic regression identified a combination of APTT >35s and platelet count ≤100 
x109/L, as predictors of bleeding risk. An elevated PT >13.5s was not significantly 
associated. Three patients (0.09% of the total cohort) died from massive intraperitoneal 
haemorrhage; all had been acutely unwell prior to the procedure. Individual coagulation 
parameters were not described. One patient had decompensated hepatitis C virus (HCV) 
cirrhosis and a focal liver lesion, the second had decompensated cirrhosis with an underlying 
glycogen storage disorder, and the third had severe graft-versus-host disease with hepatic 
involvement following a previous bone marrow transplant. Arterial embolisation and surgical 
intervention were attempted but unsuccessful [38].  
 
Bleeding complications following percutaneous liver biopsies remains overall though a rare 
event. A total bleeding rate of 0.6% (16/2740 procedures) was identified in a cohort of 
patients with HCV and advanced fibrosis or cirrhosis enrolled in the HALT-C trial. Bleeding 
risk was higher in patients with a platelet count of less than 60x109/L, while none of the eight 
patients with an INR above 1.5 experienced bleeding complications [39].  
 
In our centre, percutaneous liver biopsies require a platelet count of above 50x109/L and INR 
less than 1.5; outside these parameters, transjugular liver biopsies are preferred, without 
necessitating prophylactic transfusions. For radiofrequency ablation of hepatocellular 
carcinoma, we require a platelet count of above 70x109/L and INR below 1.8. We do not 
routinely correct deranged coagulation parameters for abdominal paracentesis, banding of 
oesophageal varices or central venous cannulation in stable cirrhotic patients; experienced 
operators are recommended to minimise procedural bleeding risks. 
  
Our practice remains the same for patients with compensated and decompensated cirrhosis, 
provided there is no active bleeding. Invasive procedures in cirrhotic patients with renal 
failure, sepsis or disseminated intravascular coagulation, however, pose greater uncertainty as 
the fragile haemostasis equilibrium is disrupted. There is an apparent paucity of literature in 
this area, thus the best approach to procedure management in these patients has not been 
established. Acknowledged limitations of standard coagulation tests also provides additional 
challenges. In cirrhotic patients with renal failure, we opt for more conservative platelet 
thresholds due to anticipated platelet dysfunction, transfusing a single pool of platelets for a 
pre-procedure platelet count of less than 80x109/L. In patients with sepsis our standard 
practice is unchanged, except in cases of disseminated intravascular coagulation, where due 
to considerably augmented bleeding risks we aim to correct deranged coagulation parameters 
prior to invasive procedures to achieve a target INR of less than 1.5 and platelet count above 
50x109/L. 
 
Empirical transfusion strategies prior to invasive procedures 
 
In a retrospective study of 1595 cirrhotic patients across 11 tertiary-care hospitals in China, 
14.8% of patients received one or more plasma transfusions during their hospital admission. 
The majority of plasma transfusions (73.3%) were administered to patients without signs of 
bleeding, and in 70.4% of cases there were no planned invasive procedures [40].  
 
There is a recognisable lack of well-powered randomised controlled trials to provide evidence 
based pre-procedure transfusion guidelines. Recently updated recommendations from the 
British Committee for Standards in Haematology advise platelet transfusion thresholds 
according to procedure type; less than 50x109/L for percutaneous liver biopsy or major 
surgery, less than 20x109/L for central venous line insertion, and no routine platelet 
transfusion for bone marrow aspiration or trephine biopsy. No specific recommendations for 
cirrhotic patients are defined [41].  
 
Traditionally patients with cirrhosis have been empirically transfused with plasma or pro-
haemostatic agents prior to invasive procedures in an attempt to reduce bleeding 
complications. Evidence supporting this practice is however lacking, and a sizeable 
proportion of inpatients with cirrhosis end up receiving unnecessary transfusions. An INR 
above 1.5 and a haemoglobin level less than 8g/dL represent arbitrary thresholds used to 
guide pre-procedure prophylactic FFP and red blood cell (RBC) transfusions respectively, 
although this practice remains essentially habit driven rather than evidence-based [15]. UK 
[42] and Baveno VI [14] guidelines for the management of variceal bleeding in cirrhotic 
patients recommend RBC transfusion to a target haemoglobin between 7g/dL and 8g/dL, with 
consideration for individual patient factors and haemodynamic stability. 
 
A UK nationwide prospective audit of 1313 consecutive patients with cirrhosis across 85 
hospitals, found that 30% of patients were transfused at least one blood product during 
admission. In 61% of cases this was for treatment of bleeding, and in 39% for prophylaxis. 
There were no planned invasive procedures in 61% of patients that were prophylactically 
transfused. In the bleeding group, 25% of patients received RBC transfusion for a 
haemoglobin ˃8g/dL, 40% received FFP for an INR<1.5, and 46% received platelets for a 
pre-transfusion platelet count ≥50x109/L. In the prophylaxis group, in the absence of 
bleeding, 29% of patients received FFP, 20% received RBC for a haemoglobin ˃8g/dl, and 
36% received platelets prior to procedures for a platelet count ≥50x109/L [43]. The 
widespread practice of unnecessary transfusions in this patient population carries a significant 
financial impact and increases demands on an already scarce resource.  
 
A single-centre observational study evaluating hospital blood product use, showed that 
patients with liver disease disproportionately received 32.4% of all FFP administered, the 
majority for pre-procedure prophylaxis [44]. However, no clear benefit to this practice has 
been demonstrated. In a case series of 363 cirrhotic patients, the transfusion of platelets or 
FFP prior to invasive procedures led to only a modest improvement in platelet count or INR, 
without any evidence for clinical benefit, and in the majority of cases not achieving 
normalisation of coagulation parameters. In fact, no bleeding events occurred in all 89 
patients with platelet counts below 50x109/L, challenging the widely-employed platelet 
transfusion threshold [37].  
 
As well as increased healthcare costs from the unnecessary transfusion of blood products, the 
risks of inflicting harm need to be considered. Although rare, transfusion related adverse 
reactions after FFP have been demonstrated, including transfusion-related acute lung injury, 
bacterial infections and volume overload [45]. Over-transfusion of RBC in the context of 
variceal bleeding is associated with worse outcomes, likely due to a rise in portal venous 
pressure. A RCT of 921 patients with severe acute upper gastrointestinal bleeding showed 
that a restrictive transfusion strategy (transfusion for a haemoglobin below 7g/dL) in cirrhotic 
patients was associated with reduced rates of re-bleeding and fewer adverse events compared 
to a liberal transfusion strategy (transfusion for a haemoglobin below 9g/dL). Subgroup 
analysis further demonstrated a lower mortality rate with restrictive transfusion for patients 
with Child Pugh A or B cirrhosis [46].  
 
The practice of transfusing platelets pre-procedure remains arbitrary, as neither a threshold 
value to trigger transfusion nor an effective target platelet count to aim for have been 
established [2]. In a cohort of 26 thrombocytopenic patients with cirrhosis (platelet count 
<50×109/L) undergoing variceal ligation, the transfusion of a single adult platelet pool was 
barely able to increase the platelet count. There was no significant effect on thrombin 
generation, and while a marginal improvement in thromboelastography occurred, no patients 
reached normal values. Whether more vigorous transfusion strategies aimed at achieving 
greater increases in platelet levels may normalise global haemostasis results and confer true 
prognostic benefit remains to be elucidated [5]. 
 
Initial studies evaluating the use of thrombopoietin receptor agonists prior to elective invasive 
procedures in patients with cirrhosis, demonstrate a rise in platelet counts thus reducing 
platelet transfusion requirements, but with no established reduction in bleeding events (53-
57). In a single-centre double-blinded RCT of 292 cirrhotic patients (platelet count 
<50x109/L), avoidance of platelet transfusions prior to elective procedures was achieved in 
72% of patients who received 14-days of eltrombopag, compared with 19% of patients in the 
placebo group (p<0.001). Higher pre-procedure platelet counts achieved by the treatment 
group did not improve bleeding outcomes; however, the risk of thrombotic events increased 
when the platelet count exceeded 200x109/L. Thrombosis of the portal venous system was 
observed in six patients in the eltrombopag group compared with one patient in the placebo 
group, resulting in early termination of the study (54). Therefore, eltrombopag is not 
currently recommended as an alternative to platelet transfusions in cirrhotic patients with 
thrombocytopenia undergoing invasive procedures. Other thrombopoietin receptor agonists, 
romiplostim and avatrombopag, show efficacy in improving platelet counts but detailed data 
regarding adverse events are not provided and larger scale RCTs are required (55-57).  
 Coagulation factor concentrates, such as recombinant factor VIIa and prothrombin complex 
concentrate, have also been suggested as potential alternatives to reduce bleeding risk [47, 
48]. Case reports for the prophylactic use of factor VIIa prior to invasive procedures in stable 
cirrhotic patients with a prolonged INR have been described [48], however strong evidence 
for its efficacy is lacking, and concerns remain over its cost effectiveness and pro-thrombotic 
potential. A multicentre RCT found no significant effect of recombinant factor VIIa therapy 
on controlling 24-hour bleeding, preventing clinically significant re-bleeding or improving 
day five mortality following variceal bleeding in patients with advanced cirrhosis. No overall 
difference in adverse events was demonstrated compared to placebo, though arterial 
thromboembolic events were only observed in the factor VIIa treatment group [49]. RCTs are 
underway to assess the impact of pre-operative administration of prothrombin complex 
concentrate on perioperative blood loss and transfusion requirements during liver 
transplantation [47].  
 
VETs guided pre-procedure transfusions 
 
The first clinical use of TEG in patients with liver disease was to guide the administration of 
pro-haemostatic products in patients undergoing liver transplantation [18]. However, the 
efficacy of TEG guided transfusion strategies in reducing bleeding risks from other invasive 
procedures remains under evaluation. Moreover, the proposed TEG cut-off values for 
transfusion are subject to great variability. 
 
In a prospective trial of 28 patients undergoing liver transplantation, patients monitored intra-
operatively by TEG received significantly less FFP compared to patients monitored by 
standard coagulation tests (mean 12.8 units vs. 21.5 units), with no difference in three-year 
survival [50]. Similarly, a significant reduction in RBC, FFP and platelet transfusions with 
ROTEM-guided haemostasis management was observed in a prospective study of 200 
patients undergoing liver transplantation. The incidence of blood product free 
transplantations increased from 5% to 24% [51].  
 
A single-centre open label RCT compared a TEG-guided pre-procedure transfusion protocol 
against standard of care in 60 cirrhotic patients (60% Child Pugh C) with significant 
coagulopathy, defined as an INR>1.8 and/or a platelet count<50x109/L. Abdominal 
paracentesis was the most commonly performed procedure, and endoscopic variceal banding 
was the most common high-risk procedure. All patients in the control group received blood 
products, compared to five patients in the TEG group (100% vs. 16.7%, p<0.0001). In both 
groups transfusion occurred more commonly in low-risk rather than high-risk procedures. 
Post-procedure bleeding was experienced by only one patient in the control group, with a pre-
transfusion INR of 2.03 and platelet count of 111x109/L, who underwent large volume 
paracentesis and had received prior FFP. No difference in 90-day survival was observed 
between the two groups [52]. A very low procedure bleeding risk (1.7%) was thus 
demonstrated, even in predominantly Child Pugh C patients. The bleeding risk was not 
related to coagulopathy or the use of transfusion products. A TEG-guided transfusion 
protocol resulted in 83.3% fewer blood products being used; moreover, the TEG thresholds 
used for transfusion (FFP if reaction time was >40min and/or platelets if maximum amplitude 
was <30mm) may be conservative and could be re-evaluated to further reduce unnecessary 
blood product use [52]. Additional RCTs are needed to validate these findings.  
 
Conclusions 
 Cirrhosis is no longer considered to be a hypocoagulable state; in-vitro studies demonstrate 
the existence of a re-balanced haemostasis equilibrium, but this can easily be disturbed. In 
fact, patients with cirrhosis paradoxically often exhibit more of a pro-thrombotic tendency. 
 
The risks of bleeding from invasive procedures in stable cirrhotic patients appears to be low, 
even in the presence of abnormal coagulation parameters. Empirical pre-procedure 
transfusion of blood products remains unnecessarily high due to arbitrary transfusion 
thresholds being relied upon, despite insufficient evidence for any clinical benefit. 
Conventional coagulation tests are limited in their ability to predict bleeding risk in cirrhosis 
and a growing body of evidence now questions their efficacy in guiding transfusion 
decisions.  
 
There is a pressing need for more reliable and comprehensive coagulation tests that 
accurately represent the complex coagulopathy of cirrhosis and help guide the management 
of thrombotic or haemorrhagic complications. The use of VETs at present lacks sufficient 
evidence for routine clinical use but warrants further evaluation. In the meantime, given 
limitations in accurately predicting bleeding risks, decisions to proceed with invasive 
procedures in patients with cirrhosis should be made after careful consideration of risks and 
benefits.  
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Table 1  
Alterations of haemostasis in cirrhosis 
 
 Pro-haemostatic mechanisms Anti-haemostatic mechanisms 
Primary 
haemostasis 
Increased VWF 
Reduced ADAMTS-13 
Thrombocytopenia 
 
Coagulation  Increased Factor VIII 
Reduced production of 
anticoagulants: anti-thrombin 
III, protein C, protein S 
Reduced production of 
procoagulant factors II, V, VII, 
IX, X, XI, XII 
Fibrinolysis Low levels of plasminogen 
Increased PAI-1 
Increased tPA 
Reduced TAFI 
Reduced ɑ2-antiplasmin 
 
VWF, von Willebrand factor; ADAMTS-13, a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13 (VWF cleaving protease); PAI-1, plasminogen 
activator inhibitor-1; tPA, tissue plasminogen activator; TAFI, thrombin-activatable 
fibrinolysis inhibitor. 
 
 
 
 
 
  
 
Table 2 
Bleeding rates of invasive procedures in patients with cirrhosis 
 
Authors Study design Number of 
cirrhotic 
patients 
(% of Child 
Pugh grade 
A/B/C) 
Procedure types Clinically 
significant 
bleeding 
complications 
(%) 
Associations with 
bleeding complications 
Napolitano 
et al. (2017) 
[37] 
 
Prospective 
single centre 
363 
(34%/43%/23%)  
 
 
 
Low risk: 
endoscopic 
procedures, large 
volume 
paracentesis, dental 
extraction 
 
Intermediate risk: 
Percutaneous 
needle biopsy/HCC 
ablation, 
laparoscopic 
procedures 
10/363 patients 
(2.75%) 
Child Pugh A/B/C: 1/5/4 
 
PLT/INR unrelated to 
bleeding risk 
 
PLT > 50: n=10, 
PLT ≤ 50: n=0 
4 transfused PLT 
 
INR ≤1.3, n=5, 
INR >1.3, n=5 
INR range 1.10 – 1.85 
3 transfused FFP 
 High risk: Vascular 
catheterisation, 
open incision in 
body cavity/tissue 
space 
 
3 low risk/3 intermediate 
risk/4 high risk 
procedures 
Takyar et 
al. (2017) 
[38] 
 
Retrospective 
single centre, 
36-year 
period 
341/3357 
confirmed 
cirrhotic 
(Child Pugh 
grade not 
specified) 
 
Percutaneous liver 
biopsy with 
Klatskin needle 
21/3357 
procedures 
(0.63%) 
 
Bleeding associated with: 
higher ALP, higher 
bilirubin, lower albumin, 
increased biopsy size 
 
APTT >35s and platelet 
count ≤100 K/μL 
predictors of bleeding 
risk (multivariate 
backward stepwise 
logistic regression) 
 
3 died: intraperitoneal 
haemorrhage 
Shah et al. 
(2015) [34] 
 
Prospective 
multicentre  
380 
(39%/40%/21%) 
 
128 with 
coagulopathy: 
Low risk: 
abdominal 
paracentesis, 
endoscopic band 
ligation, glue 
3/380 patients 
(0.79%) 
Child Pugh A/B/C: 0/0/3 
 
All 3 had INR ≥1.5 and 
platelet ≤50,000/cum, 
and contributing factors 
(INR ≥1.5 +/-
platelet 
≤50,000/cum) 
 
252: No 
coagulopathy 
injection, 
sclerotherapy 
 
High risk: major 
surgery, central 
vein cannulation, 
percutaneous liver 
biopsy, 
chemoembolization
, endoscopic 
polypectomy 
of sepsis or AKI 
 
3 high risk/0 low risk 
procedures (p=0.061) 
 
Townsend 
et al. (2012) 
[35] 
 
Retrospective    
single centre 
240 
(Child Pugh 
grade not 
specified) 
 
Cardiac 
catheterisation 
0/240 patients 
(0%) 
No major bleeding events 
 
INR range 0.93 - 2.35 
(17 patients received 
FFP, 6 received PLT, 6 
received RBC 
transfusion) 
Jeon et al. 
(2012) [36] 
Retrospective   
single centre 
30 
(70%/27%/3%) 
Colonoscopy with 
polypectomy 
 
0/66 
procedures 
major bleeding 
2/66 mild 
bleeding (3%) 
Polyp size and 
morphology associated 
with immediate post-
polypectomy bleeding 
 
No association with 
platelet count, INR, 
Child Pugh grade 
Seeff et al. 
(2010) [39] 
 
Retrospective 
multicentre 
Biopsy total: 
2740 in HCV 
advanced 
fibrosis or Child 
Pugh A cirrhosis 
Percutaneous liver 
biopsy 
16/2740 
procedures 
(0.58%) 
Bleeding rate associated 
with platelet count 
<60,000/mm3, INR ≥1.3. 
But no patients with  
INR>1.5 had bleeding 
complications 
 
PLT, Platelets; INR, International Normalised Ratio; ALP, Alkaline Phosphatase; AKI, Acute 
Kidney Injury; FFP, fresh frozen plasma; RBC, red blood cell; APTT, activated partial 
thromboplastin time. 
 
 
 
